![Cover Image for System.Linq.Enumerable+EnumerablePartition`1[System.Char]](https://coverimages.igi-global.com/images/search-article.png)
The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro.
Christopher M Gaunt, Daniel B Rainbow, Ruairi J Mackenzie, Lorna B Jarvis, Hani S Mousa, Nicholas Cunniffe, Zoya Georgieva, J William Brown, Alasdair J Coles, Joanne L Jones
OAI: oai:www.repository.cam.ac.uk:1810/325261 • DOI: 10.17863/CAM.72717
Abstract
T cells Th17 & Tregs cells Autoimmunity Multiple Sclerosis retinoid X receptor (RXR) retinoids Adult Alitretinoin Bexarotene CD4-Positive T-Lymphocytes Cells Cultured Clinical Trials as Topic Fatty Acids Unsaturated Female Forkhead Transcription Factors Humans Leukocytes Mononuclear lymphopoiesis Middle Aged remyelination Retinoid X Receptors T-Lymphocytes Regulatory Tetrahydronaphthalenes Th17 Cells